Table 3 Direct medical costs, mean time to HCV diagnosis, number of patients who developed CHC and number of CHC cases avoided by early therapy, associated with different follow-up strategies in 7300 French HCWs occupationally exposed to HCV

Strategy	Costs* (€)	Mean time to HCV diagnosis† (months)	No of CHC cases	No of CHC cases avoided by acute HCV treatment
French strategy based on anti-HCV antibody and ALT monitoring (strategy 1)	1 324 220	2.2	2.0	24.9
European strategy based on ALT monitoring (strategy 2)	1 132 230	2.0	2.1	24.9
Baseline-US strategy based on anti-HCV antibody and ALT monitoring (strategy 3)	924 180	6.0	7.9	17.7
Alternative-US strategy based on HCV RNA testing (strategy 4)	1 303 050	1.0	1.9	25.1

*Estimated costs from exposure to death.
†Mean time from exposure to HCV diagnosis.
ALT, alanine transaminase; CHC, chronic hepatitis C; HCV, hepatitis C virus; HCW, healthcare worker.